(Q37956429)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

New insights in mucosal vaccine development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Nicolas Rochereau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christian Genin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Bernard Verrier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Stéphane Paul

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

12 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

142-154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22085556%20AND%20SRC:MED&resulttype=core&format=json

Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's patches

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Interaction of antigens and antibodies at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Transepithelial transport of immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Normal structure, function, and histology of mucosa-associated lymphoid tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

NOD1 variation, immunoglobulin E and asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

New generation of mucosal adjuvants for the induction of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immunization against bacterial diseases of the intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION *

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Poliomyelitis Prevention: Recommendations for Use of Inactivated Poliovirus Vaccine and Live Oral Poliovirus Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

A comparison of the serologic responses to oral and injectable trivalent poliovirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Present and future cholera vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Population impact of Vi capsular polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Microbial-gut interactions in health and disease. Progress in enteric vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

A short report on highlights of world-wide development of RIX4414: a Latin American experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Clinical trials of rotavirus vaccines in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

RotaTeq: Progress toward Developing World Access

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immunity and correlates of protection for rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

The role of dendritic cells, B cells, and M cells in gut-oriented immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal HIV vaccines: a holy grail or a dud?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Intestinal T lymphocytes of different rat strains in immunotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

The B-cell system in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Uptake of amplifiable fragments of retrotransposon DNA from the human alimentary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Liposome (Lipodine)-mediated DNA vaccination by the oral route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Vaccine policy changes and epidemiology of poliomyelitis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal immunogenicity of plant lectins in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Development of dome epithelium in gut-associated lymphoid tissues: association of IgA with M cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

A Pathogen-specific Epitope Inserted into Recombinant Secretory Immunoglobulin A Is Immunogenic by the Oral Route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Enteric vaccines for the developing world: a challenge for mucosal immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Sublingual vaccination with influenza virus protects mice against lethal viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immune mechanisms of allergen-specific sublingual immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immunology of tonsils and adenoids: everything the ENT surgeon needs to know.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Induction of secretory immunity and memory at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Intranasal vaccination against plague, tetanus and diphtheria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Seasonal influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immune response in humans to a nasal boost with Streptococcus mutans antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal vaccines: novel advances in technology and delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Chitosan-based delivery systems for protein therapeutics and antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucoadhesive microspheres for nasal administration of cyclodextrins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Nasal drug delivery--possibilities, problems and solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Chitosan as a novel nasal delivery system for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Adjuvant synergy: the effects of nasal coadministration of adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Nanoparticles for nasal vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Intranasal immunization against influenza virus using polymeric particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

7 January 2021

Mucosal immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Paternal antigen-bearing cells transferred during insemination do not stimulate anti-paternal CD8+ T cells: role of estradiol in locally inhibiting CD8+ T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Estradiol-induced vaginal mucus inhibits antigen penetration and CD8(+) T cell priming in response to intravaginal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

NSOM- and AFM-based nanotechnology elucidates nano-structural and atomic-force features of a Y. pestis V immunogen-containing particle vaccine capable of eliciting robust response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

Human intestinal M cells display the sialyl Lewis A antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.003